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A 27-year-old bricklayer was admitted to the South Tyrone Hospital,
Dungannon, in August 1984. He gave a two-week history of shortness of breath
and cough productive of green sputum. He had no chest pain, paroxysmal
nocturnal dyspnoea, orthopnoea or peripheral oedema. He was a non-smoker
and drank 12 pints of beer per week. He was pyrexial (temperature 99.80F) and
dyspnoeic at rest. He had a cough productive of blood-streaked sputum. The
pulse was 132/minute regular. Jugular venous pressure was not raised and the
blood pressure was 90/70 mmHg. First and second heart sounds were normal.
There was a third heart sound at the apex but no murmurs. In the chest there
were coarse and medium crepitations bilaterally in both mid and lower zones.
White cell count was 11,000 x 106 per litre (73% neutrophils, 27%
lymphocytes) and ESR 55 mm in the hour. Chest X-ray showed generalised
cardiomegaly and the lung fields showed pulmonary oedema. There were also
patchy areas of consolidation throughout the lung fields. ECG showed sinus
rhythm, rate 130/minute with a normal axis: PR interval was normal, left
ventricular and left atrial hypertrophy were present and there was T wave
inversion in V3 to V6. Blood gases showed PO2 52 mmHg and PCO2 22 mmHg.
Echocardiography showed dilatation of the left atrium and left ventricle with
reduced contractility in the posterior wall of the left ventricle. All valves were
normal and there was no pericardial effusion. The picture was consistent with
dilated cardiomyopathy. Antibodies to coxsackie, adenovirus, cytomegalovirus,
psittacosis, Q fever and mycoplasma were not raised. Sputum culture was
negative.
The diagnosis was left ventricular failure secondary to dilated cardiomyopathy
caused by a possible myocarditis in view of the short history and clinical and
echocardiographic findings. There was an associated chest infection.
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Management
He was treated with digoxin, diuretics and vasodilators and warfarin. Despite
negative sputum cultures, broad spectrum antibiotics were given and also a
short course of high dose steroids. There were runs of self-limiting ventricular
tachycardia for which he was started on mexiletine orally.
His condition improved clinically and radiologically and he was gently mobilised.
Five days after discontinuing corticosteroids he became acutely breathless and
developed a mitral regurgitant murmur with a cough productive offrothy sputum
indicating left ventricular failure. Prednisolone was recommenced (60 mg daily),
the diuretics continued and within 24 hours there was clinical and radiological
improvement. He remained stable for the next four weeks and was discharged
home. Over the next three months he required three further admissions for
treatment of left ventricular failure.
In December 1984 he was transferred to the Royal Victoria Hospital for further
investigation. Cardiac catheterisation and myocardial biopsy were performed and
the results of cardiac catheterisation are shown in the Table. Endomyocardial
biopsy examination by light and electron microscopy showed the features of a
cardiomyopathy. The myocardial fibres were in disarray with a variation in fibre
diameter; there was considerable variation in nuclear size, and mitochondrial
aggregates werefound withintheinterstitium. There wasnoinflammation, fibrosis
or amyloid deposits. There were no features present on which to make an
aetiological diagnosis.
TABLE
Cardiac catheterisation data
Site Pressure (mmHg)
Right atrium a 21
v 17
mean 14
Right ventricle Systolic 53
End diastolic 10
Pulmonary artery 49/31
Pulmonary wedge a 32
v 39
Left ventricle Systolic 89
End diastolic 32
Aorta 89/61
Left ventricular
ejection fraction 13%
Angiography
Left ventricle: Markedly enlarged. Contraction very poor, all wall movements
uniformly reduced. Some mitral regurgitation into enlarged left atrium
Right ventricle: Markedly enlarged and contracted poorly. Marked tricuspid
regurgitation present.
Conclusion: Congestive cardiomyopathy.
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His subsequent course was one of progressive congestive heart failure despite
digoxin, intensive diuretic and vasodilator therapy. He required inotropic support
(intravenous dobutamine infusion) and despite these measures his cardiac
function continued to deteriorate. Progressive hyponatraemia and uraemia
developed. The only chance for survival appeared to be cardiac transplantation
and he was transferred to Papworth Hospital, Cambridge, in February 1985 for
assessment for transplantation. As he was so ill from a low cardiac output state a
'red alert' was circulated for a donor heart. A suitable donor became available on
22 February 1985.
Operative and Post-Operative Course (Papworth Hospital, Cambridge)
The donor heart was implanted and defibrillated from ventricular fibrillation into
sinus rhythm. This was followed by a short period of complete heart block.
Isoprenaline infusion was maintained for five days and atrial pacing continued for
14 days. On stopping the atrial pacing, the heart maintained normal sinus rhythm
at a rate of 75 to 80 per minute.
Pre-operatively he was given cyclosporin A and azathioprine, but because of
deterioration in renal function post-operatively cyclosporin A was discontinued
and he was maintained on azathioprine. He received corticosteroids at first intra-
venously and then orally until day 10 when the steroids were stopped and
cyclosporin A recommenced. The azathiaprine was continued. There were no
rejection episodes in the first two months.
As renal function had deteriorated prior to operation, he had to be dialysed whilst
on cardiopulmonary bypass. Post-operatively he again had deteriorating re'nal
function necessitating change in his immunosuppressive therapy. On day 10 his
renal function started to improve and on discharge his blood urea was 9.7
mmol/l. He was transferred from the intensive care unit to the general ward on
day 17 post-operatively. He had a gradual convalescence and was discharged
from hospital on the 54th post-operative day. He returned home and has
continued convalescence there without complication. His cardiac function is now
Grade I (New York Heart Association).
Pathology of the Resected Heart
The heart weighed 405 gm. All four valves were normal. Both ventricles were
dilated, theright ventricle measuring 5 x 3 x 8 cm and the leftventricle measuring
7 x 8 cm. The coronary arteries were normal. Microscopically there were wavy
myocytes and there was moderate hypertrophy of the myocytes in the left
ventricle. In the left ventricle there were some areas of contraction bands and two
foci of lymphocytic and eosinophilic infiltration in the lateral and septal walls.
There was no fibrosis or amyloid present. The findings were consistent with a
congestive cardiomyopathy.
DISCUSSION
The first human-to-human heart transplantation was performed in Cape Town in
December 1967.1 Since then, several hundred patients have undergone cardiac
transplantation in 22 countries throughout the world, the largest centre being at
Stanford, California. The primary indication for cardiac transplantation is severe
cardiac failure unresponsive to conventional therapy and due to irreversible
disease of the myocardium of the left ventricle. The patient should be 15 to 50
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years with a stable social and psychiatric background, with no active or chronic
chest infection and no insulin-dependent diabetesor recent pulmonary infarction.
The donor should be between the ages of 15 and 35 years, with no history of
cardiac disease, systemic infection or extracranial malignancy. All donor hearts
used in the Papworth programme have been removed at the referring hospital by
a surgical team from the transplant unit. The diagnosis ofbrain death in the donor
and the maintenance of ventilation and haemodynamic stability of the donor
patients are the responsibility of the referring clinicians. The donor heart is
removed, rapidly cooled and stored in cold cardioplegic solution at 2-40C and
transported to Papworth, the desirable upper limit of transit being four hours.2
During the five-year period January 1979 to December 1983, 62 hearts were
used from a total of 250 offers.2 Seventy-seven were rejected on medical criteria,
and 80 hearts were not used because of insufficient local facilities.
Therecipientisplacedon cardiopulmonary bypass. Fororthotopic transplantation
as in our patient the heart is excised leaving the posterior walls of both atria and
their venous connections in situ. The aorta and pulmonary artery are divided
immediately distal to the aortic and pulmonary valves. The donor atria (including
the sino-atrial node) are sutured to the corresponding structures in the recipient,3
as are the aorta and pulmonary artery.
Heterotopic transplantation as performed by Barnard since 1974 now involves
biventricular bypass, with anastomoses between recipient and donor right atriae,
left atriae, aortae and pulmonary arteries. Heterotopic transplantation carries the
potential advantage of leaving in situ the recipient's own right ventricle which is
often healthyormaybehypertrophied inresponsetoraised pulmonary resistance.
The recipient's own heart may also provide support for the circulation while the
donor heart function is compromised by transit-induced ischaemia or acute
rejection. The overall survival rates at one, two and three years for heterotopic
transplantation were 64%, 50% and 40% respectively. I
Rejection is most frequent in the first three months with an average frequency
during this time of one episode per 22 patient days, decreasing to one episode
per 325 patient days after the first year.3 The aim is now to detect activation
of the immune response system by immunological monitoring using sheep red
cell rosette formation and endocardial biopsy before rejection has become
established.4,5 Chronic rejection is an insidious process which obliterates the
donor coronary arteries, and is assessed by annual coronary angiography. The
incidence ofgraft arteriosclerosis at Stanford has improved since the introduction
of anti-thrombotic agents, with a graft arteriosclerosis rate of 35% in five years.4
Seventeen out of 27 patients transplanted at Papworth from 1977 to 1981 were
alive at the end of 1981,3 and 50 out of 94 patients operated on at Stanford
between 1973 and 1978 survived four years.4 In terms of quality of life, 90% of
patients transplanted at Stanford up to August 1976 and surviving three months
post-transplantation returned to New York Heart Association Grade 1. The
developmentof malignant neoplasms intransplant recipientshasbeen recognised
since 1968,6 particularly among thosewith renal transplants. During thefollow-up
of 141 patients with heart transplants from Stanford between 1968 and 1977
malignant neoplasms developed in 11 patients. The time interval from transplant-
ation to diagnosis of malignancy ranged from 135 days to 78 months.
At 1982 prices the estimated cost per patienttransplanted at Papworth, including
pre-operative assessment and first year post-operative follow-up is ofthe order of
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£15,000.3 The major component of this bill is the cost of post-operative
surveillance for rejection and infection. If an immunosuppressive 'magic bullet'
were available - effective but non-toxic - the cost ofhearttransplantation could
be reduced to little more than the cost of routine open heart surgery. From 1979
to 1983, 40% of patients selected for transplantation died whilst waiting for a
heart to become available.2 An adequate supply of donor hearts requires aware-
ness by intensive care clinicians that the need exists, and their willingness to ask
for the organ to be donated. Out of a total of 250 offers concerning cardiac
donation, only on 19 occasions was consent withheld by relatives,2 and many
hearts were offered by relatives agreeing to donation of kidneys, and then asking
if other organs could also be donated. Transplant teams acknowledge the
difficulty in asking distressed relatives for permission to transplant organs, but
feel justified by the benefit which other patients stand to gain.
Human cardiac transplantation, either orthotopic or heterotopic, has been
performed in several hundred patients in 22 centres throughout the world. It
offers an increase in survival and improved quality of life to those with terminal
cardiac failure forwhom conventional therapies are ineffective. Sofartwo patients
from this province, both with congestive cardiomyopathy, have had successful
transplants. Success ofthe procedure depends on an awareness among clinicians
throughout the country - both that such a facility exists for suitable patients, and
that a demand exists for a steady supply of suitable donor hearts.
We are grateful to Mr Terence English and Mr Richard Cory-Pearce for permission to publish details of
this case, and to Mrs Caroline O'Reilly for typing the manuscript.
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